learning-disability-treatment-market

Learning Disability Treatment Market By Therapy (Stimulant Medication, Non Stimulant Medication, Orton-Gillingham Interventional Therapy, Occupational Therapy, Assistive Technology), By Indication (Attention Deficit Hyperactivity Disorder (ADHD), Dyslexia, Dyspraxia, Others) - Growth, Future Prospects & Competitive Analysis, 2021 – 2029

26 May 2019 Format PDF icon PPT icon XLS icon Request Sample

Industry Outlook

The learning disability treatment market is set to reach US$ 30,493.1 Mn by 2029 from US$ 17,418.0 Mn in 2020 highlighting steady growth at a compounded annual growth rate (CAGR) of 6.5% during the forecast period from 2021 to 2029.  Children with learning disability have tremendous mental ability but due to irregular impulses generated by the central nervous system they suffer with altered behavior and lower cognitive skills. If diagnosed at an early stage with proper medical intervention will improve the quality of life of the patient suffering with learning disability.

"Excellent therapeutic efficacy and rising popularity among psychiatrist drive the demand for stimulant and non stimulant medication"

Stimulant and non-stimulant medication are leading the therapy segment for learning disability treatment market. Psychoactive drugs such as Ritalin, Focalin, Dexedrin and Vynase are prescribed for improving the central nervous system activity by blocking the uptake of catecholamines such as dopamine and norepinephrine. Non stimulants are also prescribed to treat depression and anxiety encountered in few patients suffering with ADHD. Assistive technology is gaining huge traction owing to its ability to provide cognitive behavioral therapy and occupational therapy in the form of learning applications and software to aid teachers in helping kids with dyslexia and dyspraxia.

"Comprehensive evaluation test and critical assessment of underlying language skills results in early diagnosis of dyslexia"

Dyslexia is reigning the indication segment for learning disability treatment market. According to the research findings brought forward by International Dyslexia Association (IDA), the prevalence rate of dyslexia in children qualifying for special education is 6-7%. The core problem associated with dyslexia is difficulty in word recognition, reading and writing fluency etc. Comprehensive evaluation test and critical assessment of underlying language skills results in early diagnosis of dyslexia and interventional therapy. Attention deficit hyperactivity disorder (ADHD), has a worldwide prevalence rate of 2.2%, with high occurrence in male in comparison to female. Effective clinical guidelines have been designed by psychiatrist worldwide with effective combination of pharmacological drugs and occupational and cognitive behavioral therapy for the effective treatment of ADHD.

"Rising prevalence of ADHD and proactive government initiatives to promote awareness and treatment for mentally disabled childrens drives the market growth in North America"

North America is presently dominating the regional segment for learning disability treatment market holding a market share of 32.5%. The major factor responsible for its outstanding market growth are rising prevalence of attention deficit hyperactivity disorder (ADHD), as per the statistics provided by the American Psychiatric Association (APA) in 2016, approximately 6.1 million children were diagnosed with ADHD in North America. Proactive government initiatives to promote awareness and treatment for mentally disabled children further bolster the market growth. Europe represents 29% market share on account of rising prevalence of dyslexia across all age group. According to the research findings of European Dyslexia Association (EDA), the prevalence rate of dyslexia is between 9 to 12% of the population. Asia Pacific holds 18.5% market share owing to the rampant growth in schools and institutes to treat children with learning disabilities and significant rise in assistive technology focusing on the development of learning software and applications in compliance with occupational therapy.

IT-Healthcare in collaboration with pharmaceutical companies actively participating in the learning disability treatment market are CogniFit, Eli Lilly & Company, Forest Laboratories, Inc., IMSE, Novartis AG, Pfizer, Inc., Shire, Plc., Therapro, Inc., Tumble N’ Dots, Inc. and Texthelp Ltd.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Learning Disability Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Learning Disability Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Therapy
  • Stimulant Medication
  • Non Stimulant Medication
  • Orton-Gillingham Interventional Therapy
  • Occupational Therapy
  • Assistive Technology

Indication
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Dyslexia
  • Dyspraxia
  • Others

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Learning Disability Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Learning Disability Treatment market?
  • Which is the largest regional market for Learning Disability Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Learning Disability Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Learning Disability Treatment market worldwide?
Choose Licence Type
$4500
$6500
$9000
Why Acute
View Other Reports